Back

FAST-STEM: A human pluripotent stem cell engineering toolkit for rapid design-build-test-learn development of human cell-based therapeutic devices

Rosenstein, A.; Sambathkumar, R.; Murareanu, B.; Dhaliwal, N.; Sun, F.; Zhao, X.; Dadvar, A.; Al-attar, R.; Chai, A.; Gulati, N.; Yin, T.; Nguyen, M.; Serra, D.; Devina, T.; Gilbert, P. M.; Kunath, T.; Laflamme, M.; Ogawa, S.; Muffat, J.; Li, Y.; Protze, S.; Nostro, C.; Garton, M. J.

2024-05-24 bioengineering
10.1101/2024.05.23.595541 bioRxiv
Show abstract

Very recent clinical advances in stem cell derived tissue replacement and gene therapy, in addition to the rise of artificial intelligence-aided scientific discovery, have placed the possibility of sophisticated human cell-based therapies firmly within reach. However, development of such cells and testing of their engineered gene circuit components, has proven highly challenging, due to the need for generating stable cell lines for each design-build-test-learn engineering cycle. Current approaches to generating stable human induced pluripotent stem cell (hiPSC) lines are highly time-consuming and suffer from lack of control, poor integration efficiency, and limited functionality. Validation in clinically relevant stem cell derived tissues is also broadly lacking. Such drawbacks are prohibitive to repeatably conducting cutting-edge stem cell engineering with broad application within a realistic timeframe and will not scale with the future of regenerative medicine. We have developed FAST-STEM (Facile Accelerated Stem-cell Transgene integration with SynBio Tunable Engineering Modes), a hPSC engineering platform that drastically reduces the time to generate differentiation ready stem cell lines from several weeks to 5 days, exhibiting a ~612-fold improvement in transgene integration rate over previous methodologies. Additional FAST-STEM innovations include: (i) rapid and highly efficient transgene integration; (ii) copy number control; (iii) simultaneous or consecutive integration of multiple gene cassettes; (iv) library screen capability. In addition to this unique functional versatility, platform transportability and broad use case for stem cell-engineering was confirmed by differentiation into eight different cell types across nine different laboratories. This platform dramatically lowers the bar for integration of synthetic biology with regenerative medicine, enabling experiments which were previously deemed logistically impossible, thus paving the way for sophisticated human cell device development.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Stem Cell Reports
130 papers in training set
Top 0.1%
18.2%
2
Stem Cell Research & Therapy
30 papers in training set
Top 0.1%
18.2%
3
Nature Communications
5641 papers in training set
Top 26%
6.2%
4
Molecular Therapy - Methods & Clinical Development
38 papers in training set
Top 0.1%
5.4%
5
Stem Cells
31 papers in training set
Top 0.1%
5.4%
50% of probability mass above
6
Molecular Therapy
81 papers in training set
Top 0.4%
4.0%
7
Advanced Science
286 papers in training set
Top 2%
3.2%
8
eLife
5828 papers in training set
Top 35%
3.2%
9
Science Advances
1243 papers in training set
Top 13%
2.7%
10
Nature Biomedical Engineering
47 papers in training set
Top 0.4%
2.4%
11
Molecular Therapy Nucleic Acids
39 papers in training set
Top 0.4%
1.9%
12
Stem Cells Translational Medicine
13 papers in training set
Top 0.1%
1.9%
13
PLOS ONE
5266 papers in training set
Top 49%
1.7%
14
Scientific Reports
3612 papers in training set
Top 55%
1.7%
15
Cytotherapy
15 papers in training set
Top 0.1%
1.7%
16
iScience
1154 papers in training set
Top 27%
1.1%
17
Communications Biology
993 papers in training set
Top 23%
1.1%
18
ACS Synthetic Biology
287 papers in training set
Top 2%
1.0%
19
Journal of Biological Engineering
12 papers in training set
Top 0.1%
0.9%
20
Cells
249 papers in training set
Top 7%
0.8%
21
Cell Reports Methods
165 papers in training set
Top 4%
0.8%
22
Molecular Therapy - Nucleic Acids
25 papers in training set
Top 0.8%
0.6%
23
npj Regenerative Medicine
24 papers in training set
Top 0.8%
0.6%
24
Tissue Engineering Part A
15 papers in training set
Top 0.3%
0.6%
25
Bioengineering & Translational Medicine
21 papers in training set
Top 0.7%
0.6%